Copyright
©The Author(s) 2021.
World J Gastroenterol. Dec 28, 2021; 27(48): 8302-8322
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8302
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8302
Figure 2 miR-135a-5p targeted vesicle-associated membrane protein 2 in hepatocellular carcinoma cells.
A: Prediction results of target gene of miR-135a-5p; B: The expression of miR-135a-5p was measured by quantitative polymerase chain reaction (qPCR) in HepG2 cells transfected with miR-135a-5p mimics; C and D: The mRNA and protein levels of vesicle-associated membrane protein 2 (VAMP2) were detected in the overexpressed miR-135a-5p cells; E: Quantification of miR-135a-5p in HepG2 cells transfected with miR-135a-5p inhibitors; F and G: qPCR and western blot analyses of VAMP2 level in HepG2 cells transfected with miR-135a-5p inhibitors; H: Luciferase assay in HepG2 cells. aP < 0.05; bP < 0.01; NS: Not Statistically Significant. GAPDH: glyceraldehyde-3-phosphate dehydrogenase; VAMP2: Vesicle-associated membrane protein 2; WT: Wild-type; MUT: Mutant.
- Citation: Wei XC, Xia YR, Zhou P, Xue X, Ding S, Liu LJ, Zhu F. Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma. World J Gastroenterol 2021; 27(48): 8302-8322
- URL: https://www.wjgnet.com/1007-9327/full/v27/i48/8302.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i48.8302